What is the long-term trend for Aura Biosciences, Inc.'s software and technology licenses, net?

Over 3 years (2022 to 2025), Aura Biosciences, Inc.'s software and technology licenses, net has grown at a 3.6% compound annual growth rate (CAGR), from $423K to $471K.

Aura Biosciences, Inc. AURA Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Johnson & JohnsonJNJ

——

Merck & Co.MRK

——

UroGen PharmaURGN

——

CG OncologyCGON

——

Relmada Therapeutics, Inc.RLMD

——

Inhibrx Biosciences, Inc.INBX

——

Other financials

Income statement

See full

Operating income-$34.9M-20.1%

Net income-$33.7M-22.6%

EPS (diluted)-$0.50+9.1%

Balance sheet

See full

Cash & equivalents$84.8M+122%

Total debt$17.0M-7.9%

Total equity$107.2M-16.2%

Total assets$137.7M-11.4%

Cash flow

See full

Operating cash flow-$29.9M-28.0%

CapEx$102.0K-45.5%

Free cash flow-$30.0M-27.4%

Valuation

See full

Market cap$709.23M+89.4%

Enterprise value$641.43M+80.8%

Returns & leverage

See full

Return on equity-95.6%+222pp

Debt / equity0.2×0.0×

Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aura Biosciences, Inc.'s software and technology licenses, net?: Aura Biosciences, Inc. (AURA) reported software and technology licenses, net of $517K in Q1 2026.
What is the long-term trend for Aura Biosciences, Inc.'s software and technology licenses, net?: Over 3 years (2022 to 2025), Aura Biosciences, Inc.'s software and technology licenses, net has grown at a 3.6% compound annual growth rate (CAGR), from $423K to $471K.